Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Oncology and Therapy
Published in: Oncology and Therapy 2/2018

Open Access 01-12-2018 | Review

Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation

Authors: Simon J. Johnston, Kwok-Leung Cheung

Published in: Oncology and Therapy | Issue 2/2018

Login to get access

Abstract

Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited in combination with established endocrine therapies to maximise efficacy. However, clinicians must balance this gain against the risk to patients of increased side effects with combination therapies. This article provides a succinct outline of the principles of hormonal manipulation in breast cancer, alongside the key evidence that underpins current clinical practice. As the role of endocrine therapy in breast cancer continues to expand, the challenge is to interpret the data and select the optimal strategy for a given clinical scenario.
Literature
1.
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–67.CrossRef
2.
3.
Beatson GT. On the Treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 1896;15:153–79.PubMedPubMedCentral
4.
5.
Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat. 1994;31(1):41–52.PubMedCrossRef
6.
Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): a review. Cancer Treat Rev. 2002;28(4):165–80.PubMedCrossRef
7.
Fisher B, et al. endometrial cancer in tamoxifen-treated breast-cancer patients—findings from the National Surgical Adjuvant Breast and Bowel Project (Nsabp) B-14. J Natl Cancer Inst. 1994;86(7):527–37.PubMedCrossRef
8.
Gradishar W. Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer. 2006;106(5):975–81.PubMedCrossRef
9.
Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003;30(4 Suppl 14):3–11.PubMedCrossRef
10.
Lonning PE, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234–44.PubMedCrossRef
11.
Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.PubMedCrossRef
12.
Johnston SJ, Cheung KL. Fulvestrant - a novel endocrine therapy for breast cancer. Curr Med Chem. 2010;17(10):902–14.PubMedCrossRef
13.
Robertson JF, et al. A good drug made better: the fulvestrant dose-response story. Clin Breast Cancer. 2014;14(6):381–9.PubMedCrossRef
14.
Robertson JF, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98(2):229–38.PubMedCrossRef
15.
Agrawal A, et al. Bone turnover markers in postmenopausal breast cancer treated with fulvestrant—a pilot study. Breast. 2009;18(3):204–7.PubMedCrossRef
16.
Baselga J, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.PubMedCrossRef
17.
Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014;40(7):862–71.PubMedCrossRef
18.
Spring LM, et al. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017;22(9):1039–48.PubMedPubMedCentralCrossRef
19.
Robertson JF, et al. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer. 1997;33(11):1774–9.PubMedCrossRef
20.
Forward DP, et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004;90(3):590–4.PubMedPubMedCentralCrossRef
21.
Bonneterre J, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18(22):3748–57.PubMedCrossRef
22.
Mouridsen H, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–9.PubMedCrossRef
23.
Paridaens RJ, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883–90.PubMedPubMedCentralCrossRef
24.
Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758–67.PubMedCrossRef
25.
Finn RS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.PubMedCrossRef
26.
Yau THL, Cheung KL. Optimising endocrine therapy in postmenopausal women with advanced breast cancer. Endocr Relat Cancer. 2018;25(7):705–21.PubMedCrossRef
27.
Hortobagyi GN, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.PubMedCrossRef
28.
Goetz MP, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46.PubMedCrossRef
29.
Di Leo A, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.PubMedCrossRef
30.
Robertson JF, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–5.PubMedCrossRef
31.
Robertson JFR, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.PubMedCrossRef
32.
Cristofanilli M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.PubMedCrossRef
33.
Johnston SR, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–98.PubMedCrossRef
34.
Bergh J, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30(16):1919–25.PubMedCrossRef
35.
36.
Kaufman B, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.PubMedCrossRef
37.
Ravdin PM, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980–91.PubMedCrossRef
38.
Wishart GC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1.PubMedPubMedCentralCrossRef
39.
40.
Jonat W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002;20(24):4628–35.PubMedCrossRef
41.
Francis PA, Regan MM, Fleming GF. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(17):1673.PubMedCrossRef
42.
Ingle JN. Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids. 2011;76(8):765–7.PubMedCrossRef
43.
Hind D, et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26):1–134 (iii–iv, ix–xi).PubMedCrossRef
44.
45.
Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: aTLAS, a randomised trial. Lancet. 2013;381(9869):805–16.PubMedPubMedCentralCrossRef
46.
47.
Fisher B, et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968;168(3):337–56.PubMedPubMedCentralCrossRef
48.
Fisher B, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–85.PubMedCrossRef
49.
Eiermann W, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–32.PubMedCrossRef
50.
Smith IE, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.PubMedCrossRef
51.
Cataliotti L, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer—the Pre-Operative “Arimidex” Compared to Tamoxilen (PROAC7) trial. Cancer. 2006;106(10):2095–103.PubMedCrossRef
52.
Kuter I, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012;133(1):237–46.PubMedCrossRef
53.
Cheung KL, Howell A, Robertson JFR. Preoperative endocrine therapy for breast cancer. Endocr Relat Cancer. 2000;7(3):131–41.PubMedCrossRef
54.
55.
56.
Bear HD, et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial. J Surg Oncol. 2017;115(8):917–23.PubMedPubMedCentralCrossRef
57.
Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer. 2007;96(7):1025–9.PubMedPubMedCentralCrossRef
58.
Wyld L, et al. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer. 2004;90(8):1486–91.PubMedPubMedCentralCrossRef
59.
Johnston SJ, Cheung KL. The role of primary endocrine therapy in older women with operable breast cancer. Future Oncol. 2015;11(10):1555–65.PubMedCrossRef
60.
Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older women with operable breast cancer—a comparison of randomised controlled trial and cohort study findings. Eur J Surg Oncol. 2014;40(6):676–84.PubMedCrossRef
61.
Johnston SJ, et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol. 2012;23(9):2296–300.PubMedCrossRef
62.
Hind D, et al. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;1:CD004272.
63.
Chakrabarti J, et al. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up. Crit Rev Oncol Hematol. 2011;78(3):260–4.PubMedCrossRef
64.
Syed BM, et al. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre. Br J Cancer. 2011;104(9):1393–400.PubMedPubMedCentralCrossRef
65.
Cheung KL, et al. Pathological features of primary breast cancer in the elderly based on needle core biopsies—a large series from a single centre. Crit Rev Oncol Hematol. 2008;67(3):263–7.PubMedCrossRef
66.
Syed BM, et al. Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. Br J Cancer. 2013;108(5):1042–51.PubMedPubMedCentralCrossRef
67.
Clauser P, et al. Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ. Expert Rev Anticancer Ther. 2016;16(3):335–46.PubMedCrossRef
68.
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–67.
69.
Dowsett M, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.PubMedCrossRef
70.
Mocellin S, et al. Breast cancer chemoprevention: a network meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2016;108(2):djv318.PubMedCrossRef
71.
Cuzick J, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–34.PubMedPubMedCentralCrossRef
72.
Chavez-MacGregor M, et al. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy ± one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140). J Clin Oncol. 2015;33(15_suppl). https://​doi.​org/​10.​1200/​jco.​2015.​33.​15_​suppl.​tps637
73.
74.
75.
Magnani L, et al. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERalpha metastatic breast cancer. Nat Genet. 2017;49(3):444–50.PubMedPubMedCentralCrossRef
Metadata
Title
Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
Authors
Simon J. Johnston
Kwok-Leung Cheung
Publication date
01-12-2018
Publisher
Springer Healthcare
Published in
Oncology and Therapy / Issue 2/2018
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-018-0062-x

Other articles of this Issue 2/2018

Oncology and Therapy 2/2018 Go to the issue

Commentary

The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria

Original Research

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan

Original Research

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Review

Mastocytosis: One Word for Different Diseases

Original Research

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Original Research

Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits